Panacea Biotec's Q2 FY 2025-26 Quarterly Results
- 1d ago
Result Summary
- Panacea Biotec Ltd reported a 14.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 2.9%.
- Its expenses for the quarter were down by 4.4% QoQ and up 12.9% YoY.
- The net profit decreased 453.8% QoQ and decreased 397.5% YoY.
- The earnings per share (EPS) of Panacea Biotec Ltd declined at 2.27 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
| (₹ crores) | Q2FY26 | Q1FY26 | Q2FY25 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 147.53 | 172.37 | 152.00 | -14.4% | -2.9% |
Total Expenses | 169.40 | 177.13 | 150.01 | -4.4% | 12.9% |
Profit Before Tax | -19.17 | 6.56 | 4.76 | -392.2% | -502.7% |
Tax | -5.16 | 2.60 | 0.05 | -298.5% | -10420.0% |
Profit After Tax | -14.01 | 3.96 | 4.71 | -453.8% | -397.5% |
Earnings Per Share | -2.27 | 0.66 | 0.77 | -443.9% | -394.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Panacea Biotec Ltd is a pharmaceutical and biotechnology company focused on the research, development, manufacturing, and marketing of vaccines, biopharmaceuticals, and pharmaceuticals. The company's product portfolio typically includes a wide range of pharmaceuticals and vaccines, catering to various therapeutic areas. As of the data available, there are no recent major developments explicitly stated. However, the company operates within the healthcare and pharmaceuticals industry, which is subject to regulatory approvals, market demand fluctuations, and ongoing research and development initiatives. Information about specific recent developments beyond October 2023 is not included in the provided data.
Revenue
For the second quarter of the fiscal year 2026 (Q2FY26), Panacea Biotec Ltd reported a total income of ₹147.53 crores. This represents a decrease of 14.4% quarter-over-quarter (QoQ) from ₹172.37 crores in Q1FY26. Year-over-year (YoY), there is a 2.9% decline from ₹152.00 crores in Q2FY25. The revenue performance indicates changes in the company's income generation capabilities over the periods compared. The decrease in total income suggests variations in sales or other income sources compared to the previous quarter and the same quarter last year.
Profitability
During Q2FY26, Panacea Biotec Ltd recorded a loss before tax of ₹19.17 crores, contrasting with a profit of ₹6.56 crores in Q1FY26 and a profit of ₹4.76 crores in Q2FY25. This reflects a substantial QoQ decline of 392.2% and a YoY decline of 502.7%. The tax impact also showed a negative value of ₹5.16 crores in Q2FY26, compared to ₹2.60 crores in Q1FY26 and ₹0.05 crores in Q2FY25, illustrating significant changes. Consequently, the profit after tax stood at a loss of ₹14.01 crores, compared to positive figures of ₹3.96 crores in Q1FY26 and ₹4.71 crores in Q2FY25. Earnings per share (EPS) followed a similar trend, moving to a negative ₹2.27 from ₹0.66 in Q1FY26 and ₹0.77 in Q2FY25.
Operating Metrics
Total expenses for Q2FY26 were ₹169.40 crores, a decrease of 4.4% from ₹177.13 crores in Q1FY26. Compared to Q2FY25, this represents an increase of 12.9% from ₹150.01 crores. The increase in expenses year-over-year indicates higher operational costs or expanded operations. The significant changes in profitability metrics, along with the expense variations, highlight fluctuations in the company's operational efficiency and cost management. Although specific operating ratios like P/E, debt-to-equity, and current ratios are not provided in the data, the reported figures offer insights into recent operational performance trends. The data underscores shifts in the financial dynamics of Panacea Biotec Ltd across different quarters and years.
FAQs
When was Panacea Biotec Ltd Q2 FY 2025-26 result announced?
Panacea Biotec Ltd announced its Q2 FY 2025-26 results on 16 November, 2025.
What are Panacea Biotec Ltd quarterly results?
Panacea Biotec Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
What were the key highlights of Panacea Biotec Ltd Q2 FY 2025-26 results?
Key highlights of Panacea Biotec Ltd Q2 FY 2025-26 results include:
- Revenue: ₹147.53 crore
- Net Profit: ₹-14.01 crore
- EBITDA: ₹-8.69 crore
- Year-over-Year Growth: -2.9%
- Quarter-over-Quarter Growth: -14.4%
How did Panacea Biotec Ltd net profit perform in this quarter?
Panacea Biotec Ltd reported a net loss of ₹-14.01 crore in Q2 FY 2025-26, reflecting a -397.5% year-over-year growth.
What was Panacea Biotec Ltd revenue in Q2 FY 2025-26?
Panacea Biotec Ltd posted a revenue of ₹147.53 crore in Q2 FY 2025-26.